mechlorethamine has been researched along with Dysmyelopoietic Syndromes in 12 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials." | 1.39 | Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. ( Advani, RH; Balise, R; Greenberg, PL; Hoppe, RT; Horning, SJ; Koontz, MZ; Rosenberg, SA, 2013) |
| "Risk of leukemia was 0." | 1.30 | The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con ( Anselmo, AP; Baroni, CD; Bernasconi, C; Brusamolino, E; Klersy, C; Lazzarino, M; Lunghi, F; Mandelli, F; Maurizi-Enrici, R; Orlandi, E; Pagnucco, G; Santoro, M, 1998) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| "2) Non-Hodgkin's lymphoma has not appeared in any of the patients in this series." | 1.28 | [Second neoplasms as a late complication of the treatment of Hodgkin's disease]. ( Alvarez, A; Colomé, JA; del Potro, E; Díaz Mediavilla, J; González, FA; Martínez, R; Morales, MD; Villegas, A, 1992) |
| "20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle." | 1.28 | ABEP as primary chemotherapy for Hodgkin's disease. ( Alberto, P; Mermillod, B; Zulian, GB, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koontz, MZ | 1 |
| Horning, SJ | 1 |
| Balise, R | 1 |
| Greenberg, PL | 1 |
| Rosenberg, SA | 1 |
| Hoppe, RT | 1 |
| Advani, RH | 1 |
| Metayer, C | 1 |
| Curtis, RE | 1 |
| Vose, J | 2 |
| Sobocinski, KA | 1 |
| Horowitz, MM | 1 |
| Bhatia, S | 1 |
| Fay, JW | 1 |
| Freytes, CO | 1 |
| Goldstein, SC | 1 |
| Herzig, RH | 1 |
| Keating, A | 1 |
| Miller, CB | 1 |
| Nevill, TJ | 1 |
| Pecora, AL | 1 |
| Rizzo, JD | 1 |
| Williams, SF | 1 |
| Li, CY | 1 |
| Travis, LB | 1 |
| Weisdorf, DJ | 1 |
| Kneller, A | 1 |
| Cohen, N | 1 |
| Berkowicz, M | 1 |
| Reichart, M | 1 |
| Rosner, E | 1 |
| Sokolovski, M | 1 |
| Nagler, A | 1 |
| Rechavi, G | 1 |
| Amariglio, N | 1 |
| Trakhtenbrot, L | 1 |
| Anderson, JR | 1 |
| Kessinger, A | 1 |
| Corti, C | 1 |
| Theodore, C | 1 |
| Bayle, C | 1 |
| Rougier, P | 1 |
| Nasr, F | 1 |
| Cosset, JM | 1 |
| Girinsky, T | 1 |
| Hayat, M | 1 |
| Ribrag, V | 1 |
| Brusamolino, E | 1 |
| Anselmo, AP | 1 |
| Klersy, C | 1 |
| Santoro, M | 1 |
| Orlandi, E | 1 |
| Pagnucco, G | 1 |
| Lunghi, F | 1 |
| Maurizi-Enrici, R | 1 |
| Baroni, CD | 1 |
| Lazzarino, M | 1 |
| Mandelli, F | 1 |
| Bernasconi, C | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Hudson, GV | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 1 |
| Hancock, B | 1 |
| Winfield, D | 1 |
| MacMillan, AK | 1 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Milligan, D | 1 |
| Linch, DC | 1 |
| Morales, MD | 1 |
| González, FA | 1 |
| Villegas, A | 1 |
| del Potro, E | 1 |
| Díaz Mediavilla, J | 1 |
| Martínez, R | 1 |
| Alvarez, A | 1 |
| Colomé, JA | 1 |
| Zulian, GB | 1 |
| Mermillod, B | 1 |
| Alberto, P | 1 |
| Iurlo, A | 1 |
| Mecucci, C | 1 |
| Van Orshoven, A | 1 |
| Michaux, JL | 1 |
| Boogaerts, M | 1 |
| Van den Berghe, H | 1 |
| Sizoo, W | 1 |
| Hagenbeek, A | 1 |
| Löwenberg, B | 1 |
| Blayney, DW | 1 |
| Longo, DL | 1 |
| Young, RC | 1 |
| Greene, MH | 1 |
| Hubbard, SM | 1 |
| Postal, MG | 1 |
| Duffey, PL | 1 |
| DeVita, VT | 1 |
12 other studies available for mechlorethamine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Californ | 2013 |
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2003 |
Acquisition of a Ph chromosome with minor BCR/ABL fusion in treatment-related myelodysplastic syndrome with chromosome 7 abnormalities in a patient treated for Hodgkin disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Chromosome | 2005 |
Myelodysplastic syndrome after autologous transplant for lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Dis | 1994 |
High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubi | 1996 |
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con
Topics: Abdomen; Actuarial Analysis; Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; | 1998 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |
[Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1992 |
ABEP as primary chemotherapy for Hodgkin's disease.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabin | 1992 |
The karyotype in secondary hematologic disorders after treatment for Hodgkin's disease. A study of 19 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Hodgkin Disea | 1988 |
[Myelodysplastic syndromes: a group of preleukemic disorders].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia | 1987 |
Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; | 1987 |